Targeting the PI3K-Akt-signaling pathway could strengthen remission of acute myeloid leukemia (AML) through enhancing the drug sensitivity,27 and this pathway here was specifically enriched by the remission gene set. This evidence concerns the gene AKT1 and acute myeloid leukemia.